The results of experimental studies have indicated the pleiotropic effects of statins in organism, e.g. the influence on cell cycle, apoptosis or angiogenesis. In this study, the effects of simvastatin on selected parameters of apoptosis and proliferation in chemocarcinogen-induced mammary tumorigenesis in female rats were determined. Simvastatin was administered dietary at a dose of 18 mg/kg and highly effective dose of 180 mg/kg the entire experiment (18 weeks). At autopsy mammary tumors were removed and prepared for immunohistochemical and histomorphological analysis. In treated animals (simvastatin 180 mg/kg), significant decrease by 12% in Bcl-2 protein expression and non-significant decrease by 27% of Ki67 protein expression in tumor cells compared to tumor cells in control animals were observed after semiquantitative evaluation. Morphometrical analysis has shown significant proapototic shift in Bcl-2/Bax ratio in tumor cells. In high grade control carcinoma cells, the expression of Ki67 increased by 37% (non-significantly) in comparison with control low grade carcinomas. A histomorphological analysis of malignant tumors has revealed a shift from high grade to low grade carcinomas after simvastatin treatment. The noticeable decrease of mammary tumor frequency and incidence in rats after simvastatin treatment was accompanied with antiapoptotic Blc-2 protein decrease and proapoptotic Bax protein increase in this experiment.
Statins are 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA) inhibitors with important role as hypolipidemic agents [1] . Within the last ten years, the results of experimental studies have indicated the pleiotropic effects of statins in organism which are mediated by their direct or indirect influence on cell cycle, apoptosis or angiogenesis. These physiological processes play a key role in neoplastic transformation, for this reason statins are seriously discussed by clinical and experimental oncologists.
Statins reduce not only serum cholesterol levels but also mevalonate synthesis. Mevalonate is a precursor of several major products regulating the cell cycle, including dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) [2] . Another product -geranylgeranylpyrophosphate (GGPP) can be synthesised from FPP. Both FPP and GGPP are substrates essential for the activation of variety protooncogenes, e.g. the inhibition of mevalonate pathway by statins can consequently block the Ras or Rho activation [3] . Statins have been shown to stabilize the cell cycle kinase inhibitors p21 and p27, and to arrest breast cancer cell lines in the G1 phase of the cell cycle [2] .
Proposed mechanisms for statin-mediated apoptosis include an upregulation of pro-apoptotic protein expression (e.g., Bax, Bim), combined with decreased anti-apoptotic protein expression (e.g., Bcl-2) [4] , or activation of caspase-3, caspase-517 PATHOLOGY OF RAT MAMMARY TUMORS: EFFECT OF SIMVASTATIN 8 , and caspase-9 [5] . In the study of Agarwal et al. [6] it has been shown that addition of geranylgeranylated pyrophosphate prevented lovastatin induced apoptosis in colon cancer cells, whereas cotreatment with farnesyl pyrophosphate had no effect. This study also showed that lovastatin treatment resulted in decreased expression of the antiapoptotic protein Bcl-2 and increased expression of proapoptotic protein Bax in cancer cells. In esophageal adenocarcinoma cells, statin treatment increased mRNA and protein expression of proapoptotic proteins Bax and Bad, but protein levels of antiapoptotic proteins Bcl-2 and Bcl-X-L were unchanged [7] . In another study, the anticarcinogenic potential of fluvastatin was evaluated in three hepatocellular carcinoma cell lines (HepG2, SMMC-7721 and MHCC-97H). After fluvastatin treatment, expression of Bcl-2 and procaspase-9 were downregulated, cytochrome c (cytosolic extract), Bax and cleaved-caspase-3 protein expression increased [8] . In this context, pro-apoptotic shift of ratio in Bax/Bcl-2 mRNA expression in rat mammary tumor cells caused by atorvastatin in our previous experiment was confirmed [9] .
The above mentioned observations have led us to hypothesize that statins might inhibit also proliferation and induce apoptosis in rat mammary tumor cells in our preventivecurative model. Ki67 is an excellent marker to determine the growth fraction of a given cell population [10] . The fraction of Ki67 -positive tumor cells (the Ki67 labeling index) is often correlated with the clinical course of cancer. In this study, the immunohistochemical analysis of Ki67 and Bcl-2 and Bax proteins as the apoptotic parameters after simvastatin treatment will be determined. Another aim of this study -a histomorphological analysis of mammary tumors -may have implications for assessment of simvastatin on the differentiation and prognosis of the tumors after long-term treatment and or the efficacy of drug.
Materials and methods
Female rats of Sprague-Dawley strain obtained from AnLab (Prague, Czech Republic) aged 31-35 days were used in the experiment. The animals were adapted to standard vivarium conditions with temperature 23 ± 2 °C, relative humidity 40-60 %, artificial regimen light : dark (12 h : 12 h) (lights on from 6 a.m., light intensity 150 lux per cage). During the experiment the animals were fed by the Ssniff diet (Soest, Germany) and drank tap water ad libitum. Mammary carcinogenesis was induced by N-methyl-N-nitrosourea (NMU) (Sigma, Deisenhofen, Germany) administered intraperitoneally in one dose of 50 mg/kg body weight on average the 41 th postnatal day. In the last -18 th week of the experiment, the animals were quickly decapitated, mammary tumors were excised and tumor size was recorded. Macroscopic changes in selected organs (liver, kidney, stomach, intestine and lung) were evaluated at autopsy. The parameters of mammary carcinogenesis (tumor incidence, frequency, latency and volume) were evaluated in each experimental group. Tissue samples of each mammary tumor were routinely formalin-fixed and paraffin-embedded. The tumors were classified according to the criteria for the classification of rat mammary tumors [11] . The additional parameter -grade of invasive carcinomas was used. Tumor samples were divided into low-grade (LG) and high-grade (HG) carcinomas. The criteria for categorization -solidization, cell atypia, mitotic activity index, and necrosis, were chosen according to the standard diagnostic method of classification. As HG carcinomas were considered tumors with ≥2 positive criteria, LG carcinomas were tumors with ≤ 1 positive criterium. The solidization was considered if >30% of tumor sample displays solid growth, high mitotic activity index if ≥10 mitosis was observed in 10 high power fields and necrosis if the occurrence of comedo (not infarct) was determined.
The paraffin block having the most representative tumor area of each mammary tumor was chosen for immunohistochemical analysis of Ki67, Bcl-2 and Bax protein expression. A Table 1 summarizes the clone, source concentration, and 
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time of incubation of antibodies used in experiment. Immunohistochemical staining was evaluated by a semiquantitative method based on percentage representation of positively responded elements. Positivity of staining was assessed as percentage of positive cells. The only criterion of positivity in semiquantitative method was the difference against negative stromal component. In the Bcl-2/Bax ratio evaluation, a morphometrical analysis as a method for precise analysis of protein expression in tumor cells was used. In morphometry, the expression of markers (positivity) was evaluated from the set limit. Moreover in this method not only carcinoma cells were evaluated but also stromal elements ("all the cells of tumor tissue"). Possible differences in results between semiquantitative and morphometrical analysis arise from different threshold positivity setting and from different spectrum of evaluated elements. Morphometric analysis of the digital images was done by software QuickPhoto Micro version 2.3 (Promicra, Prague, Czech Republic). Phase analysis function was used for the quantitative determination of Bcl-2 and Bax immunohistochemically positive cells. The area of labeled cells was percentually evaluated with standard thresholds for weak, mild and strong intensity /for three degrees of intensity/ of immunoreactivity in standard fields. Protein expression of Bcl-2 and Bax was analysed in the cytoplasm of tumor cells separately. During interphase, Ki67 can be exclusively detected within the nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes. The Ki67 protein is present during all active phases of the cell cycle, but is absent in resting cells, therefore it is an excellent marker for determining the growth fraction of cell population. Photographs were taken by an Olympus BX41, digital camera model No. SP 350. MannWhitney -U test, Kruskal-Wallis and one-way analysis of variance were statistical methods used in data evaluation in this experiment.
Results
This experiment is a continuation to our previous study where the significant tumor-suppressive effects of simvastatin (SIMVA 180) in the chemoprevention of rat mammary carcinogenesis were observed [12] . Simvastatin administered at a lower dose (SIMVA 18) did not change parameters of mammary carcinogenesis; therefore immunohistochemical analysis was realized only in rat mammary tumor cells from the control and the SIMVA 180 group.
A histopathological classification of mammary tumors has revealed a shift in the rate of poorly differentiated (high grade, HG) and well differentiated (low grade, LG) invasive tumors to higher representation LG invasive tumors after treatment with simvastatin [control group: 16/17 (HG/LG); SIMVA 18: 11/20; SIMVA 180: 1/2]. The treatment with simvastatin in higher dose apparently changed the rate from malignant to benign lesions (control group -33/3, SIMVA 180 -3/4) ( Table 2 ).
The expression of Ki67, Bcl-2 and Bax proteins as percentage of positive cells in treated and control tumor cells and in control low grade and high grade invasive tumors were evaluated by semiquantitative method ( Table 3 control group simvastatin group expression of Bcl-2 and Bax did not significantly differ between control LG and control HG invasive tumor cell groups. In addition to the above mentioned statistical analysis, in the tumor cells from treated group (compared to control tumor cells), more frequent occurrence of some histomorphological signs of apoptosis were observed -shrinking of the cells, fragmentation of the nucleus, dense cytoplasm, karyorhexis, apoptotic bodies.
Discussion
This experiment is the first report about simvastatin used in mammary carcinogenesis in female rats. A significant chemopreventive effect of simvastatin administered in the concentration of 180 mg/kg of the diet was recorded in all parameters of mammary carcinogenesis. In addition, simvastatin in this experimental group was also effective in the 521 PATHOLOGY OF RAT MAMMARY TUMORS: EFFECT OF SIMVASTATIN treatment of tumors -the drug distinctly reduced the number of malignant lesions in favour of benign tumors. Moreover, a histopathological analysis of mammary tumors has revealed a shift from poorly to well differentiated invasive tumors after simvastatin administration (180 mg/kg). On the other hand, the lower concentration of simvastatin -18 mg/kg in our experiment (equivalent to daily clinical doses) was ineffective in animals. Similarly, significant antitumor effects of atorvastatin (100 mg/kg of diet) administered in the chemoprevention of NMU-induced rat mammary carcinogenesis in our previous study were observed [9] . In our last experiment, hydrophilic rosuvastatin (250 mg/kg of diet) has shown lower chemopreventive activity than lipophilic statins in this model of experimental breast cancer [13] . Narisawa et al. [14] in 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice, used as a chemopreventive agent dietary administered simvastatin at concentrations of 0.01% (100 mg/kg) and 0.002% (20 mg/kg) and pravastatin administered in drinking water at concentrations of 0.01%, 0.001% and 0.005%. Both agents significantly reduced tumor frequency. Anticarcinogenic effects of statins were proved also in other in vivo experiments. Pravastatin administered in drinking water has been shown to reduce the incidence and volume of N-nitrosomorpholineinduced hepatic neoplastic nodules in Sprague-Dawley rats [15] and to reduce N-methyl-N-nitrosourea induced F344 rat colon carcinogenesis [16] .
Recent in vitro studies have proven direct or indirect effects of statins on regulation mechanisms of the cell e.g. proliferation or apoptosis. Antiproliferative effects of statins include the inhibition of dolichol, geranylpyrophosphate and farnesylpyrophosphate, the stabilization of the cell cycle kinase inhibitors p21 and p27 and inhibition of Ras-and Rhomediated cell proliferation [2, 3] . Emerging data indicate that statins demonstrate antiproliferative effects in several types of proliferating tumor cells. In vitro studies on various cell lines have shown that statins stimulated inhibitory potential, either by induction of G1-arrest or G2/M-arrest [17, 18] . Zhang et al. [8] have observed that fluvastatin inhibited proliferation of hepatocellular carcinoma cell lines (HepG2, SMMC-7721 and MHCC-97H) by inducing apoptosis and G2/M phase arrest in a dose-dependent manner. In another experiment, acquired data demonstrated that lovastatin inhibits the proliferation of MART-1-specific human cytolytic T lymphocytes without affecting cytolytic capacity [19] . In the study of Bessler et al. [20] malignant cell lines -HuCC, EHEB, K562, and Raji were incubated with three lipophilic statins (atorvastatin, lovastatin, and simvastatin) and one hydrophilic statin (pravastatin). All used statins inhibited HuCC cell proliferation. EHEB and K562 cell proliferation was inhibited by the lipophilic statins, but not by pravastatin. Raji cell proliferation was not affected by any of the used statins. The results of this experiment pointed out that the antiproliferative effect of statins on tumor cells depends on their dosage, physiochemical property, and the type of the malignant cells. Additionally, cerivastatin induced G1-arrest in breast cancer cells, but signs of apoptosis were not observed [3] . These results suggest that statin-induced effects on proliferation and apoptosis are independent. Ki67 is a cancer antigen that is found in growing, dividing cells but is absent in the resting phase of cell growth. This characteristic makes Ki67 a good tumor marker, e.g. meta-analysis of De Azambuja et al. [21] suggested that Ki67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early breast cancer. The effect of statin on Ki67 expression in tumor cells was evaluated in a recent experimental study [22] . The nude mouse xenograft assay showed that combination of epigallocatechin-3-gallate and lovastatin suppressed esophageal cancer cell growth and reduced the expression of Ki67. In our study, the expression of Ki67 protein in mammary tumor cells was also evaluated. [24] , hepatocytes [25] and glioma cells [26] , whereas hydrophilic statins (rosuvastatin and pravastatin) have not [27] . In the recent study of Kato et al. [28] , the apoptotic potential of two lipophilic statins -lovastatin and simvastatin and one hydrophilic statin -pravastatin was assessed in ovarian, endometrial and cervical cancer cell lines. Lovastatin and simvastatin, but not pravastatin induced cell death through activation of extrinsic and intrinsic apoptotic cascades (caspase-8 and -9; BID cleavage, cytochrome C release and PARP cleavage) in cancerous cells, which expressed high levels of HMG-CoA reductase. In our study, after highly effective treatment of rat mammary tumors by simvastatin, we have evaluated the possible role of Bcl-2 and Bax proteins in the drug`s mechanism of action. Using semiquantitative and morphometrical methods, simvastatin has indicated proapoptotic shift in Bax/Bcl-2 ratio. The drug significantly decreased antiapoptotic Bcl-2 protein expression in treated tumor cells compared to tumor cells in control animals. Non-significant, but evident increase of proapoptotic Bax protein expression in the group of treated tumor cells was observed after morphometrical analysis (despite the fact that semiquantitative analysis has shown non-significant decrease of Bax expression in treated cells). The results of this study indicate an important role of Bcl-2 apoptosis-regulatory protein and probably not relevant role for Bax protein in the pathogenesis of rat mammary tumors treated by simvastatin. Some experimental evidence suggests that in breast cancer, development, progression and an increased proliferation rate can be linked to apoptosis-related factors. Similarly than in our study, Sirvent et al. [29] studied 186 cases of infiltrating ductal breast carcinoma and concluded that Bax expression did not provide a new prognostic role, although it contrasted to the Bcl-2 action. Another study summarized that a high Bcl-2 expression had prognostic value in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy [30] .
The results of this study clearly pointed to simvastatin`s antineoplastic effects in experimental rat mammary carcinogenesis. Our study is the first report about Ki67, Bcl-2 and Bax protein immunohistochemical analysis in mammary tumor cells in vivo after treatment with statin. Our results pointed out to proapoptotic and antiproliferative effects of simvastatin in rat mammary carcinogenesis. Histomorphological analysis of tumors has shown apparent shift from malignant to benign lesions and shift from high grade to low grade carcinomas after simvastatin administration; in terms of clinical use this is an interesting result because long-term applied simvastatin may improve the disease prognosis and thus lifespan in oncological patients. Anticipated proapoptotic and antiproliferative effects or antiangiogenetic and antimetastatic mechanism of action of statins along with the favourable results from clinical oncological research have provided a rationale for future use of statins as potential anticancer reagents in the growth control of breast cancer.
